The duration of response to both alectinib and lorlatinib in the patient was limited to 4–5 months, which is significantly shorter than NSCLC patients treated with first and second generation ALK TKIs, where typical duration of response is 11–36 months [16, 17, 18]. Here, ALK is linked to non-small cell lung carcinoma.